U.S. health spending is expected to grow at an average rate of 5.5 percent every year from 2018 over the next decade and will reach nearly $6 trillion by 2027 as more people become eligible for Medicare, a government health agency said on Wednesday.
(Reuters Health) - More babies could be born with heart defects in the future as global warming puts pregnant women at greater risk of exposure to dangerously high temperatures, new research suggests.
(Reuters Health) - Certain tumors labeled as "cancer" aren't life-threatening and should be called something else instead, some doctors believe.
Eli Lilly and Co on Wednesday embraced a U.S. government proposal to end a decades-old system of rebates drugmakers make to industry middlemen, saying it could lower the cost of insulin and other prescription drugs for patients.
The U.S. government's proposal to eliminate rebates that pharmacy benefit managers receive from drugmakers will not have a meaningful impact on growth, and does not affect the commercial market, Cigna Corp Chief Executive Officer David Cordani said on Friday.
(Reuters Health) - - Medical students in Boston are teaching local high school students about CPR, and the younger students say they feel better prepared to help in cases of cardiac arrest, should the need arise.
Anthem Inc surprised Wall Street on Wednesday by moving up the launch of its in-house pharmacy benefits management business, sending shares 10 percent higher as investors welcomed the decision after rival health insurers signed multibillion-dollar deals joining forces with PBMs.
Jan 29 Pfizer Inc on Tuesday reported
fourth-quarter profit and sales that edged past Wall Street
estimates, helped by higher sales of breast cancer medicine
Ibrance and pain drug Lyrica.
(Reuters Health) - Women with inflammatory bowel disease (IBD) can have healthy pregnancies with proper planning and care, according to a new initiative from a major medical society aimed at dispelling myths surrounding the disease.
AbbVie Inc said on Friday it expects a steeper decline in overseas sales of its top-selling drug, Humira, due to intense competition from cheaper versions in Europe, driving its shares down nearly 7 percent.